SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Corporation Release: Recruitment Complete for Two Pivotal Phase III Studies of nintedanib* in Patients With Idiopathic Pulmonary Fibrosis